Abstract
Background/Aims: Critically-ill patients often undergo continuous renal replacement therapy (CRRT) and need antimicrobial therapy. Piperacillin and tazobactam (Pip-Tzb) are cleared by CRRT. Our aim is to evaluate Pip-Tzb removal in an in-vitro-single-pool-model of continuous-veno-venous-hemofiltration (CVVH); we test a new method of Pip-Tzb administration during CRRT assuring constant levels of concentrations above the minimum inhibitory concentration (MIC).
Methods: In an in-vitro-single-pool-model of CVVH, two solutions (Protein-Free-Solution, PFS and Fresh-Frozen- Plasma, FFP) added with Pip-Tzb were tested for Pip-Tzb removal and adsorption. Then, to keep concentrations constantly above the MIC during CVVH, we add Pip-Tzb in the reinfusion bags.
Results: Pip-Tzb rapidly decreased than the MIC during CVVH. The adsorption was irrelevant in the test with FPS. Adding Pip-Tzb in the reinfusion bags of the CVVH system, we observed constant concentrations of Pip-Tzb over time.
Conclusion: The association of Pip-Tzb is rapidly cleared with a real risk of inadequate dosages in patients undergoing CRRT. Adding Pip-Tzb in the reinfusion bags above the MIC, we obtained stability of concentrations during CVVH.
Keywords: Antibiotic, antimicrobial therapy, continuous renal replacement therapy, continuous venovenous hemofiltration, drug clearance, dyalisis, in vitro investigation, infection, minimum inhibitory concentration (MIC), piperacillin, sepsis, tazobactam.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Drastic Reduction of Piperacillin-Tazobactam Concentrations in an in-vitro Model of Continuous Venovenous Hemofiltration: Proposal of An Innovative Modality of Administration to Maintain them at Constant Concentration
Volume: 11 Issue: 3
Author(s): Michele Ferrannini, Pasquale Niscola, Clorinda Falcone, Annalisa Noce, Anna Pastore, Gianna Di Giovamberardino, Andrea Tendas, Laura Scaramucci, Nicola Di Daniele and Roberto Palumbo
Affiliation:
Keywords: Antibiotic, antimicrobial therapy, continuous renal replacement therapy, continuous venovenous hemofiltration, drug clearance, dyalisis, in vitro investigation, infection, minimum inhibitory concentration (MIC), piperacillin, sepsis, tazobactam.
Abstract: Background/Aims: Critically-ill patients often undergo continuous renal replacement therapy (CRRT) and need antimicrobial therapy. Piperacillin and tazobactam (Pip-Tzb) are cleared by CRRT. Our aim is to evaluate Pip-Tzb removal in an in-vitro-single-pool-model of continuous-veno-venous-hemofiltration (CVVH); we test a new method of Pip-Tzb administration during CRRT assuring constant levels of concentrations above the minimum inhibitory concentration (MIC).
Methods: In an in-vitro-single-pool-model of CVVH, two solutions (Protein-Free-Solution, PFS and Fresh-Frozen- Plasma, FFP) added with Pip-Tzb were tested for Pip-Tzb removal and adsorption. Then, to keep concentrations constantly above the MIC during CVVH, we add Pip-Tzb in the reinfusion bags.
Results: Pip-Tzb rapidly decreased than the MIC during CVVH. The adsorption was irrelevant in the test with FPS. Adding Pip-Tzb in the reinfusion bags of the CVVH system, we observed constant concentrations of Pip-Tzb over time.
Conclusion: The association of Pip-Tzb is rapidly cleared with a real risk of inadequate dosages in patients undergoing CRRT. Adding Pip-Tzb in the reinfusion bags above the MIC, we obtained stability of concentrations during CVVH.
Export Options
About this article
Cite this article as:
Ferrannini Michele, Niscola Pasquale, Falcone Clorinda, Noce Annalisa, Pastore Anna, Giovamberardino Di Gianna, Tendas Andrea, Scaramucci Laura, Daniele Di Nicola and Palumbo Roberto, Drastic Reduction of Piperacillin-Tazobactam Concentrations in an in-vitro Model of Continuous Venovenous Hemofiltration: Proposal of An Innovative Modality of Administration to Maintain them at Constant Concentration, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/187152571103140120102359
DOI https://dx.doi.org/10.2174/187152571103140120102359 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Dynamic TRPA1 Channel: A Suitable Pharmacological Pain Target?
Current Pharmaceutical Biotechnology Role of Quality Management System (QMS) for Effective Regulatory Compliance
Applied Clinical Research, Clinical Trials and Regulatory Affairs 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review
Cardiovascular & Hematological Disorders-Drug Targets Nanomaterials for Neurology: State-of-the-Art
CNS & Neurological Disorders - Drug Targets Gender-Specific Relationship Between Uric Acid Levels and Prognosis After Cerebral Venous Thrombosis
Current Neurovascular Research Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study
Current Vascular Pharmacology Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry The Fundamental Role of Medical Treatment in the Prevention of Carotid Related Strokes: Insights from a Multispecialty Consensus Document
Current Vascular Pharmacology Nitric Oxide Control of Proliferation in Nerve Cells and in Tumor Cells of Nervous Origin
Current Pharmaceutical Design Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Neuroprotective Effects of Trolox, Human Chorionic Gonadotropin, and Carnosic Acid on Hippocampal Neurodegeneration After Ischemiareperfusion Injury
Current Stem Cell Research & Therapy The Possible Mechanisms for β-glucans to Prevent Atherosclerotic Lesions
Current Bioactive Compounds Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology